-

Northlane Capital Partners Invests in The Difference Card

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today that it has made an investment in EBS, Inc. d/b/a The Difference Card (“The Difference Card”), a leading provider of healthcare cost containment solutions. NCP invested in partnership with The Difference Card’s existing management team, led by CEO Gregg Lehman. Richard Fleder, an executive with more than 45 years of experience in the health insurance benefits industry, joined the Board of Directors in conjunction with NCP’s investment.

Founded in 2001, The Difference Card enables employers to reduce healthcare costs without reducing employees’ benefit levels or increasing employees’ out-of-pocket expenses. The Difference Card typically targets small and mid-sized businesses and serves nearly 800 employers across the U.S. in various end markets. Additional information is available at https://www.differencecard.com/.

“Our partnership with NCP comes at an exciting time for The Difference Card. NCP brings both resources and end market expertise that will help us accelerate our growth initiatives, including adding new client and insurance broker partnerships, expanding geographically, and developing new products,” said Gregg Lehman, CEO of The Difference Card.

Sean Eagle, Partner at NCP, noted, “The Difference Card provides a compelling value proposition to companies throughout the U.S. As healthcare costs continue to rise, employers continue to seek ways to save money, while maintaining or improving benefits. The company is well-positioned to continue addressing this need through its unique solution.”

Eugene Krichevsky, Partner at NCP, added, “We are very excited to partner with The Difference Card. The team has done a great job building a differentiated offering, and we are committed to supporting its mission of providing cost-effective health insurance benefits to customers and their employee bases.”

ABOUT NORTHLANE CAPITAL PARTNERS

Based in Bethesda, MD, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested more than $1.5 billion of equity capital. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value. NCP was recently named to Inc.'s 2020 Private Equity 50 list of the top founder-friendly private equity firms and Grady Campbell’s 2021 list of Top 50 Private Equity Firms in the Middle Market. For more information, please visit www.northlanecapital.com.

Contacts

Sean Eagle, Partner
(301) 841-1377

Eugene Krichevsky, Partner
(301) 841-1399

Chase Edmonds, Vice President
(240) 319-4102

Northlane Capital Partners


Release Summary
Northlane Capital Partners Invests in The Difference Card
Release Versions

Contacts

Sean Eagle, Partner
(301) 841-1377

Eugene Krichevsky, Partner
(301) 841-1399

Chase Edmonds, Vice President
(240) 319-4102

Social Media Profiles
More News From Northlane Capital Partners

Northlane Capital Partners Announces Investment in Plus Delta Partners

CARLSBAD, Calif.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today that it has made an investment in Plus Delta Partners (“PDP”), a leading provider of specialized fundraising training and tools designed to enable higher education institutions, healthcare organizations, and other nonprofits to maximize donor contributions. NCP invested alongside PDP’s management team and its founder, Guy Hart. PDP offers a comprehensive suite of fundraising training solutions tailored to fron...

Northlane Capital Partners Invests in United States Drug Testing Laboratories

DES PLAINES, Ill.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today that it has invested in United States Drug Testing Laboratories Inc. (“USDTL”), a forensic toxicology laboratory testing for alcohol and substance use. NCP invested alongside USDTL’s management team and its founders, Veronica and Doug Lewis. USDTL is headquartered in Des Plaines, IL, and offers a broad suite of forensic testing capabilities. The company primarily serves hospitals, health systems, court system...

SAI MedPartners Expands Strategic Service Offering Through Acquisition of IDEA Pharma

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired IDEA Pharma (“IDEA”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022. IDEA, headquartered in London, United Kingdom, specializes in pharmaceutical path-to-market strategy and innovation. This acquisition strengthens SAI’s ca...
Back to Newsroom